Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7
Ilaria Lamberto(Dana-Farber Cancer Institute), Sara J. Buhrlage(Harvard University), Wanyi Hu(Dana-Farber Cancer Institute), Deepika Sharma Das(Dana-Farber Cancer Institute), Roxana E. Iacob(Northeastern University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Sirano Dhe‐Paganon(University of Toronto), Nathan J. Schauer(Dana-Farber Cancer Institute), Ellen Weisberg(Dana-Farber Cancer Institute), Hyuk‐Soo Seo(Dana-Farber Cancer Institute), John R. Engen(Northeastern University), Tatiana Mikhailova(Harvard University), Xiaoxi Liu(Sichuan University), Dharminder Chauhan(Cancer Clinic)
Cited by 188
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k